검색어: acetylcholinesterase (영어 - 슬로베니아어)

acetylcholinesterase
acetilholin-esteraza

in vitro, this metabolite shows minimal inhibition of acetylcholinesterase (<10%).
in vitro kaže ta presnovek zelo majhno stopnjo zaviranja holinesteraze (< 10 %).

rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
rivastigmin deluje tako, da zavira encima, ki razgrajujeta acetilholin: acetilholinesterazo in butirilholinesterazo.

analyses of acetylcholinesterase (ache) may also be performed on these samples, if deemed appropriate.
na teh vzorcih se po potrebi lahko izvedejo analize acetilholinesteraze (ache).

the active substance in rivastigmine 3m health care ltd, rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
zdravilna učinkovina v zdravilu rivastigmin 3m health care ltd, rivastigmin, deluje tako, da zavira encime, ki razgrajujejo acetilholin: acetilholinesterazo in butirilholinesterazo.

as rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours.
ker ima rivastigmin plazemski razpolovni čas okrog 1 ure in traja njegovo zaviranje acetilholinesteraze okrog 9 ur, priporočamo, da v primeru asimptomatičnega prevelikega odmerka bolnik v naslednjih 24 urah ne prejme nadaljnjih odmerkov rivastigmina.

in healthy young men, an oral 3 mg dose decreases acetylcholinesterase (ache) activity in csf by approximately 40 % within the first 1.5 hours after administration.
pri zdravih mladih moških peroralni odmerek 3 mg zmanjša aktivnost acetilholinesteraze (ache) v cerebrospinalni tekočini (csf) za približno 40 % v poldrugi uri po zaužitju.

a meta-analysis of patients with moderate to severe alzheimer’ s disease (mmse total scores < 20) from the six phase iii, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
meta- analiza bolnikov z zmerno do hudo alzheimerjevo boleznijo (skupna ocena kpss ob vključitvi < 20), ki je zajela 6 študij faze iii, kontroliranih s placebom in trajajočih 6 mesecev (vključno s študijami zdravljenja v monoterapiji ter študij bolnikov na stabilnem odmerku inhibitorjev acetilholinesteraze), je pokazala statistično značilen učinek v korist zdravljenja z memantinom na področjih spoznavnih funkcij ter globalnih in funkcionalnih domen.